GlassScriptPhysician profile
Corey R Weaver
NPI 1922586361
$6,477.91
in general payments reported to CMS, 2019-2025
24 companies · $3,387 in 2025
The $3,387 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $616 · 2022: $317 · 2023: $624 · 2024: $1,533 · 2025: $3,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,368 · Travel and Lodging: $1,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,368.04 |
| Travel and Lodging | $1,176.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,825.32 | 2025 | Neurostar Tms Therapy System |
| Alkermes, INC. | $745.93 | 2021-2025 | Aristada, Lybalvi |
| Abbvie INC. | $651.81 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $481.97 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $391.14 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $369.55 | 2022-2025 | Caplyta |
| Lundbeck LLC | $343.09 | 2024-2025 | Rexulti |
| Corium, LLC | $258.82 | 2023-2025 | Azstarys |
| Axsome Therapeutics, INC. | $210.66 | 2023-2025 | Auvelity |
| Tris Pharma INC | $197.70 | 2023-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $195.51 | 2024-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $156.58 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $112.69 | 2025 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $104.06 | 2022-2024 | |
| Neos Therapeutics, LP | $92.39 | 2024-2025 | Adzenys Xr-Odt |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $63.46 | 2022-2023 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $59.56 | 2024-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $53.17 | 2022-2025 | Quviviq, Quviviq |
| Supernus Pharmaceuticals, INC. | $43.99 | 2023-2024 | Qelbree, Qelbree |
| Brainsway USA INC | $36.07 | 2025 | Deep Tms System |
| Neurocrine Biosciences, INC. | $25.39 | 2025 | |
| Itamar Medical INC | $23.75 | 2024-2025 | Watchpatone |
| Noven Therapeutics, LLC | $20.73 | 2025 | Xelstrym |
| Collegium Pharmaceutical, INC. | $14.57 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.